Conxita Jacobs Cachá

Featured in: Favicon

Articles

Correspondence on: ‘SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy’ by Zhao et al

May 15, 2024 | ard.bmj.com | Maria Soler |Conxita Jacobs Cachá |Hans-Joachim Anders |Policlinic IV

Correspondence on: ‘SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy’ by Zhao et al Free Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Correspondence on: ‘SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy’ by Zhao et al

Jan 3, 2024 | ard.bmj.com | Maria Soler |Hans-Joachim Anders |Policlinic IV |Conxita Jacobs Cachá

Lupus NephritisLupus Erythematosus, SystemicAutoimmune DiseasesWe read with interest and surprise the study of Zhao et al. on the therapeutic effects of the SGLT2 inhibitor empagliflozin in systemic lupus erythematosus (SLE) and lupus-like nephritis of MRLlpr mice.1 The concerns are the following: (1) SGLT2 is a sodium-glucose transporter mainly expressed in the proximal tubule of the kidney.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.